ANTISOMA bricht gerade ein!!!!!!! o.T.
Seite 1 von 1 Neuester Beitrag: 22.02.02 11:20 | ||||
| Eröffnet am: | 22.02.02 10:33 | von: MM-TT | Anzahl Beiträge: | 7 |
| Neuester Beitrag: | 22.02.02 11:20 | von: Dr.UdoBroem. | Leser gesamt: | 1.775 |
| Forum: | Hot-Stocks | Leser heute: | 1 | |
| Bewertet mit: |  | |||
Antisoma reveals £22 million share offer to stave off bankruptcy
Antisoma has revealed plans for a £22 million share issue after its six-month losses widened.
Pre-tax losses rose to £6.09 million, from £3.95 million.
Revenues hit £1.1 million, from £1.7 million.
The company has warned that it faces bankrpuptcy if shareholders don`t approve the rights issue.
Antisoma`s financial difficulties worsened last June, when US regulators turned down its lead product pemtumomab, a treatment for ovarian cancer.
The company was forced to pay for additional clinical trials to prove the drug`s effectiveness.
Chairman Barry Price said the rights issue will allow the company to continue development of its products.
The group has nine products in development, and expects to have six products in clinical trials by the end of 2002.
Antisoma said the company is not likely to reach profitability until after one or more of its products receives marketing approval in the US or Europe, and builds up sales.
Story filed: 07:48 Friday 22nd February 2002
Ich würde zu dem Kurs nicht verschenken
hallo leute der niedergeschlagenen art ANTISOMA war monate mein Problem habe sie dann verkauft und mir Worldcom aktien gekauft na ja dann bin ich da raus und in comroad rein ihr seht nichts kann mann mehr glauben, einen aufschwung werden wir dieses jahr wohl nicht mehr sehen. Ich glaube eher das wir noch so einige Kurseinbrüche und entäuschungen sehen werden, wo wir alleeeee dachten die sind Super, na ja momentan ComRoad größter beschisssssssssssssss.
Zu ANTISOMA ich glaube das wenn sie genug geld hätten zum arbeiten noch zwei bis drei jahre für hre entwicklungen der preparate brauchen, da aber das geld ca. nur noch für ein halbes jahr reicht das zu diesem zeitpunkt, werden wir wieder einen abstiegskandidaten sehen, oder es gibt geld und alles läuft so beschissen weiter wie bisher
MFG
TB
Post: Elan Halts Alzheimer's Vaccine Test
WASHINGTON (Reuters) - Embattled Irish drugmaker Elan Corp. (NYSE:ELN - news;
quote from Yahoo! UK & Ireland: ELN.L) has halted trials of an experimental Alzheimer's
vaccine after 12 volunteers became ill with brain inflammation, The Washington Post reported
on Friday.
The newspaper quoted sources familiar with the study as saying there was little question the vaccine, code named AN-1792, triggered brain reactions, which some scientists said was encephalitis.
A company spokesman told the newspaper an independent committee was reviewing data from the study involving about 360 patients with mild to moderate Alzheimer's disease in four European countries and 11 U.S. sites.
The report on the vaccine adds to Elan's problems, which include a battered share price, a grim 2002 profit warning and a U.S. Securities and Exchange Commission investigation into allegations of deceptive accounting practices.
According to the Washington Post, the vaccine aims to generate an immune system attack against ``beta amyloid,'' the brain protein believed to be at the root of Alzheimer's. Experiments in mice suggested the vaccine could halt the progression of Alzheimer's and perhaps even cure the deadly disease, the paper said.
Although animal studies and early human safety studies suggested the vaccine was reasonably safe, the test was controversial
because immune reactions typically cause inflammation, the report said.
Elan, which is developing the vaccine with Wyeth-Ayerst Laboratories, the pharmaceutical division of Madison, New
Jersey-based American Home Products Corp. (NYSE:AHP - news) would not say how quickly it had halted inoculations after
the first few patients were diagnosed with problems.
The company mentioned the problem in a joint press release with Wyeth posted on its Web site on Jan. 18 reporting on
developing in the clinical trail of AN-1792.
``The companies have decided to temporarily suspend dosing in this Phase 2A study after four patients in France were
reported to have clinical signs consistent with inflammation in the central nervous system,'' the statement said. ``All four patients
are receiving appropriate medical care and the companies are working with clinical investigators to determine the cause of this
development.''
Citing sources in contact with Elan officials, the paper said since that statement, the number of patients that had developed
serious problems has climbed to 12.
